23andMe Showcases Breakthroughs in Clinical Immuno-oncology
23andMe's Groundbreaking Contributions to Immuno-oncology
23andMe Holding Co. (Nasdaq: ME), a leader in human genetics and biopharmaceutical advancements, is set to present exciting updates on its clinical immuno-oncology programs, specifically 23ME-00610 and 23ME-01473, during the prestigious ESMO Congress 2024. This event will take place from September 13 to September 17 in Barcelona and highlights the innovative strides 23andMe is making in the realm of cancer therapy.
Analyzing New Clinical Data
The company will unveil pivotal preliminary data from the renal cancer and TMB-H/MSI-H cohorts within its Phase 1/2a clinical trial for 23ME-00610, a pioneering anti-CD200R1 antibody. Notably, 23andMe is also set to share insights from analyses assessing CD200 as an exploratory tissue-based biomarker linked to the efficacy of 23ME-00610.
Preclinical Insights and Ongoing Trials
In addition, 23andMe aims to present preclinical data regarding 23ME-01473, an anti-ULBP6 monoclonal antibody, which is currently undergoing dose escalation studies. These studies began in March 2024 and focus on how 23ME-01473 can target soluble ULBP6, a factor that contributes to an immunosuppressive environment within tumors.
Clinical Trial Highlights from ASCO
Diving deeper into its recent trial findings, 23andMe showcased encouraging results at the American Society of Clinical Oncology (ASCO) meeting. Monotherapy with 23ME-00610 proved to have a promising safety profile alongside early evidence of clinical benefits in cohorts challenging advanced cancers. Among the highlights was a confirmed partial response in a patient with pancreatic neuroendocrine cancer.
Innovative Biomarkers Locations
Research on CD200 is particularly intriguing, as findings suggest it may serve as a potential tissue-based biomarker, further enhancing precision in cancer treatment. This marks a significant step towards personalized medicine approaches based on genetic and immunological assessments.
Detailed Presentation Information
Here are the key details regarding the presentations that will be made at ESMO:
- Abstract: 1069TiP
Title: A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody for Patients with Advanced Solid Malignancies
Session Type: Poster Session – Investigational Immunotherapy
Date and Time: September 14, 9:00-17:00 CEST - Abstract: 620P
Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with TMB-H and/or MSI-H Cancers: Results from an Expansion Cohort
Session Type: Poster Session – Developmental Therapeutics
Date and Time: September 14, 9:00-17:00 CEST - Abstract: 153P
Title: 23ME-01473 Restores Anti-Tumor NK Cell Function Through NKG2D and FcgRIIIa Activation
Session Type: Poster Session – Biomarkers and Translational Research
Date and Time: September 15, 9:00-17:00 CEST - Abstract: 1706P
Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Session Type: Poster Session – Renal Cancer
Date and Time: September 15, 9:00-17:00 CEST - Abstract: 150P
Title: Phase 1/2a Trial of CD200R1 Inhibitor 23ME-00610; Exploratory Analyses of Biomarkers
Session Type: Poster Session – Biomarkers and Translational Research
Date and Time: September 15, 9:00-17:00 CEST
Understanding the Innovations
23ME-00610 is designed to block the interaction between CD200R1 and CD200, targeting the CD200–CD200R1 axis, a critical immunological checkpoint for controlling immune tolerance. Targeting this pathway could restore the ability of immune cells to fight cancer more effectively.
On the other hand, 23ME-01473 works by restoring anti-tumor immune responses through Natural Killer (NK) and T cells by targeting the ULBP6 ligands that cancer cells commonly shed to evade detection. This mechanism enhances the immune response against tumors, potentially changing the landscape of cancer immunotherapy.
About 23andMe
23andMe is at the forefront of integrating genetic data into healthcare solutions and developing biopharmaceutical products that promise a healthier future for all. They leverage genetic insights obtained from millions of participants to explore and validate potential treatments rooted in genetic predispositions.
Frequently Asked Questions
What new trials will 23andMe present at ESMO Congress 2024?
23andMe will present trials related to its anti-CD200R1 antibody, 23ME-00610, and the anti-ULBP6 monoclonal antibody, 23ME-01473.
What is 23ME-00610?
23ME-00610 is a first-in-class monoclonal antibody targeting CD200R1, aimed at enhancing immune responses against cancer.
What is the significance of CD200 in cancer treatment?
CD200 serves as an immunological checkpoint; blocking its pathway could restore immune function in cancer patients.
How does 23ME-01473 function?
23ME-01473 targets soluble ULBP6 to encourage NK and T cell recognition of cancer cells, restoring anti-tumor immunity.
What role does 23andMe's genetic database play?
The genetic database enables 23andMe to discover drug targets by correlating genetic variants with immune response and cancer risk.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lerner Publishing Group Expands Portfolio with New Acquisition
- Understanding Nexans S.A. Share Capital and Voting Rights
- Cyclacel Pharmaceuticals Pursues Hearing After Delisting Notice
- EzFill Holdings, Inc. Achieves NASDAQ Listing Compliance Again
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- Polarean Imaging Welcomes Alan Huang as VP of Sales
- Coloplast A/S Share Trading Insights for Board and Executives
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Object Management Group Launches New Journal of Innovation
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- Global Cash Handling Device Market Growth Insights
- Affiliated Network Providers and Aurora Health Join Forces
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- AGBA and Triller Finalize Amended Merger Agreement Details
Recent Articles
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Front Opening Unified Pods Market Set to Reach $93.73 Million
- Robinhood to Share Insights at Goldman Sachs Conference
- Worksport's Dealer Initiative Drives Strong Sales Growth
- Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
- Bicara Therapeutics Pursues IPO for Innovative Cancer Treatments
- Flipster Launches Earn Campaign for BTC, ETH, and USDT Rewards
- Lucid Diagnostics Partners with Front Line Mobile Health
- Kohl's vs. Visa: A Deep Dive into Dividends and Growth Potential
- Tourmaline Bio Announces Participation in Investor Conferences
- Opthea's Upcoming Presentations at Investment Conferences
- Piston Air Motors Market Projects Growth to $987 Million by 2034
- Lithium Ionic Appoints David D’Onofrio to Board of Directors
- Regenx Tech Corp Announces Production Update and Webinar
- JinkoSolar Provides Over 1,000 Solar Modules for Relief
- Mendel's Hypercube Platform Now Live on Microsoft Azure Marketplace
- Calliditas Therapeutics' Strategic Response to Asahi Kasei's Move
- Join the Class Action Against Indivior PLC (INDV) Now
- Seritage Growth Properties Investors Alert: Class Action Lawsuit Update
- Dior Welcomes Miu Miu CEO Benedetta Petruzzo as MD
- US Dollar Response to ISM Survey and Global Economic Factors
- AEG's Innovative Kitchen Range Unveiled at IFA 2024
- SKF Welcomes Susanne Larsson as Chief Financial Officer
- Silver Cross and Lamborghini Team Up for Luxury Stroller
- China-Africa Cooperation: Paving the Way for Modernization